Search

Barbra J Sasu

from San Francisco, CA
Age ~53
Get Report
Also known as:
Barbra A Sasu, Barbra A Johnson, Barbara J Sasu, Barbra Ann Johnson, Barbara A Johnson, Sebastian Sasu
Related to:
Hsingpei Chen, 39
Connected to:
David S Sasunian, 28Barbara Sasy, 38Michael E Sasz, 56Jacqueline Saszi, 48Sat Sat, 53Neepa K Sata, 43Vamsi Sata, 43Devin C Satabe, 33Sanjay Satagopan, 46Hiroshi Satake, 75

Barbra Sasu Phones & Addresses

  • San Francisco, CA
  • San Bruno, CA
  • 30831 Marseille Way, Thousand Oaks, CA 91362 (818) 889-7093
  • 4102 E Hillcrest Dr, Thousand Oaks, CA 91362
  • Westlake Village, CA
  • Roxbury Crossing, MA
  • Agoura, CA
  • Ventura, CA

Publications

Us Patents

Hepcidin, Hepcidin Antagonists And Methods Of Use

View page
US Patent:
20080213277, Sep 4, 2008
Filed:
Jan 30, 2008
Appl. No.:
12/022515
Inventors:
Barbra Sasu - Westlake Village CA, US
Mitsuru Hainu - Thousand Oaks CA, US
Thomas Charles Boone - Newbury Park CA, US
Xiao-Juan Bi - Thousand Oaks CA, US
Ki Jeong Lee - Westlake Village CA, US
Tara Arvedson - Simi Valley CA, US
Aaron Winters - Ventura CA, US
Keegan Cooke - Ventura CA, US
Zeqi Sheng - Thousand Oaks CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/18
C12N 15/11
C12N 15/00
G01N 33/566
A61P 43/00
C07K 1/00
C12N 5/06
C12P 21/04
G01N 33/567
US Classification:
4241411, 5303879, 5303873, 536 2353, 4353201, 435325, 435 696, 435 721, 436501, 530402
Abstract:
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.

Method Of Detecting And/Or Measuring Hepcidin In A Sample

View page
US Patent:
20090173876, Jul 9, 2009
Filed:
Jul 20, 2007
Appl. No.:
11/880313
Inventors:
Hongyan Li - Oak Park CA, US
Alan Breau - San Mateo CA, US
Barbra Sasu - Westlake Village CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
B01D 59/44
US Classification:
250282
Abstract:
Methods of isolating and/or analyzing hepcidin by mass spectrometry and methods of quantifying hepcidin are disclosed.

Ferroportin Antibodies And Methods Of Use

View page
US Patent:
20110274691, Nov 10, 2011
Filed:
Jan 23, 2009
Appl. No.:
12/863737
Inventors:
Tara Arvedson - Simi Valley CA, US
James Rottman - Sudbury MA, US
Barbra Sasu - Westlake Village CA, US
Gregory Dyas - Carnel IN, US
International Classification:
A61K 39/395
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
C12N 1/15
C12N 1/19
C12P 21/00
G01N 33/577
A61P 3/00
A61P 7/06
A61P 9/04
A61P 13/12
A61P 3/10
A61P 19/02
A61P 9/10
A61P 35/00
A61P 7/00
A61P 29/00
A61M 37/00
C07K 16/18
US Classification:
4241391, 5303879, 5303873, 536 2353, 4353201, 435331, 435419, 4352523, 43525231, 43525234, 43525235, 43525233, 43525411, 4352542, 43525421, 43525422, 43525423, 4352546, 4352544, 4352545, 4352543, 435 696, 436501, 435 721, 604500
Abstract:
Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.

Method Of Detecting And/Or Measuring Hepcidin In A Sample

View page
US Patent:
20110312888, Dec 22, 2011
Filed:
Jun 15, 2011
Appl. No.:
13/160711
Inventors:
Hongyan Li - Oak Park CA, US
Alan Breau - San Mateo CA, US
Barbra Sasu - Westlake Village CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 38/22
H01J 49/26
A61P 7/06
US Classification:
514 97, 250282
Abstract:
Methods of isolating and/or analyzing hepcidin by mass spectrometry and methods of quantifying hepcidin are disclosed.

Selective Targeting Of Host Cd70+ Alloreactive Cells To Prolong Allogeneic Car T Cell Persistence

View page
US Patent:
20220409665, Dec 29, 2022
Filed:
Jun 15, 2022
Appl. No.:
17/841041
Inventors:
- South San Francisco CA, US
Siler PANOWSKI - Berkeley CA, US
Barbra Johnson SASU - San Francisco CA, US
Cesar Adolfo SOMMER - San Mateo CA, US
Surabhi SRIVATSA SRINIVASAN - San Francisco CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Shanshan LANG - San Mateo CA, US
International Classification:
A61K 35/17
C07K 16/28
A61P 35/00
Abstract:
Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen

View page
US Patent:
20220340671, Oct 27, 2022
Filed:
Mar 15, 2022
Appl. No.:
17/695769
Inventors:
- New York NY, US
Bijan Andre Boldajipour - San Francisco CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Philippe Duchateau - Draveil, FR
Roman Galetto - Paris, FR
Alexandre Juillerat - New York NY, US
Thomas Charles Pertel - San Mateo CA, US
Arvind Rajpal - San Francisco CA, US
Barbra Johnson Sasu - San Francisco CA, US
Cesar Adolfo Sommer - San Mateo CA, US
Julien Valton - Charenton Le Pont, FR
Thomas John Van Blarcom - Oakland CA, US
International Classification:
C07K 16/28
C07K 14/725
C07K 14/705
A61K 39/00
A61K 31/7076
C12N 15/63
A61K 35/17
C12N 5/10
C12N 5/0783
Abstract:
The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Protease-Activating Cd45-Gate Car

View page
US Patent:
20220227832, Jul 21, 2022
Filed:
Dec 21, 2021
Appl. No.:
17/557654
Inventors:
- SOUTH SAN FRANCISCO CA, US
- NEW YORK NY, US
Michael Thomas BETHUNE - Castro Valley CA, US
Siler PANOWSKI - Berkeley CA, US
Nguyen TAN - Berkeley CA, US
Yi ZHANG - Foster City CA, US
Barbra Johnson SASU - San Francisco CA, US
Zhe LI - Burlingame CA, US
International Classification:
C07K 14/725
C07K 14/705
C12N 15/79
C07K 19/00
Abstract:
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

Chimeric Antigen Receptors Targeting Epidermal Growth Factor Receptor Variant Iii

View page
US Patent:
20220227874, Jul 21, 2022
Filed:
Jan 27, 2022
Appl. No.:
17/586321
Inventors:
- New York NY, US
Joyce Ching Chou - Sunnyvale CA, US
Mathilde Brunnhilde Dusseaux - Creteil, FR
Julianne Smith - New York NY, US
Barbra Johnson Sasu - San Francisco CA, US
International Classification:
C07K 16/28
C07K 14/47
C07K 14/725
Abstract:
The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
Control profile
Barbra J Sasu from San Francisco, CA, age ~53 Get Report